ImmunityBio (NASDAQ:IBRX) Hits New 52-Week High – Should You Buy?

Shares of ImmunityBio, Inc. (NASDAQ:IBRX) hit a new 52-week high during mid-day trading on Wednesday . The stock traded as high as $8.39 and last traded at $8.4750, with a volume of 66569461 shares. The stock had previously closed at $6.02.

ImmunityBio News Roundup

Here are the key news stories impacting ImmunityBio this week:

• Positive Sentiment: European Commission authorization expands ImmunityBio’s commercial footprint across four regulatory jurisdictions quickly, including key markets and additional indications for Anktiva — a major growth catalyst for sales and addressable market. What’s Behind The Jump In ImmunityBio Stock?
• Positive Sentiment: Productive regulatory discussions and a Saudi filing/“nod” for bladder cancer (BCG-related) advance market access in Saudi Arabia — investors view this as near-term revenue upside and validation in a large, well-funded market. ImmunityBio Reports Productive Regulatory Engagement with Saudi Food and Drug Authority
• Positive Sentiment: Market coverage and pre-market headlines highlighted the Saudi BCG update and growing retail interest, amplifying buying momentum. Analyst support (D. Boral Capital reaffirmed buy with a $24 PT) provides a bullish price-target narrative. How high can IBRX stock go now?
• Neutral Sentiment: Commercial performance context: Seeking Alpha notes Anktiva’s strong early commercial traction (FY25 revenue cited) and upcoming pivotal trial readouts (bladder cancer, glioblastoma) — these are major potential upside catalysts but also make valuation sensitive to trial setbacks. ImmunityBio: The Story Surrounding Anktiva So Far
• Neutral Sentiment: Reported short-interest data is anomalous/unclear (entries show zero shares / NaN); with very high trading volume, short-interest metrics may not reflect real positioning — monitor updated, reliable short-interest reports for true bearish pressure. Short Interest Data (company reports)
• Negative Sentiment: Pomerantz law firm announced an investigation on behalf of ImmunityBio investors — potential litigation or disclosure risk that could create headline-driven volatility and act as a near-term overhang. Pomerantz Law Firm Investigates Claims

Analysts Set New Price Targets

IBRX has been the subject of a number of research reports. Weiss Ratings restated a “sell (e+)” rating on shares of ImmunityBio in a report on Monday, December 29th. HC Wainwright upped their price target on shares of ImmunityBio from $8.00 to $10.00 and gave the company a “buy” rating in a report on Monday, January 26th. BTIG Research boosted their target price on shares of ImmunityBio from $6.00 to $9.00 and gave the stock a “buy” rating in a research report on Thursday, January 22nd. Jefferies Financial Group boosted their price target on shares of ImmunityBio from $8.00 to $9.00 and gave the company a “buy” rating in a research report on Friday, December 12th. Finally, D. Boral Capital reissued a “buy” rating and set a $24.00 price target on shares of ImmunityBio in a research note on Tuesday. Five investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $11.80.

ImmunityBio Stock Performance

The company has a market cap of $8.41 billion, a price-to-earnings ratio of -20.83 and a beta of 0.16. The stock’s fifty day simple moving average is $4.10 and its two-hundred day simple moving average is $2.99.

Insider Transactions at ImmunityBio

In related news, Director Christobel Selecky sold 50,000 shares of the stock in a transaction dated Friday, January 16th. The shares were sold at an average price of $5.00, for a total transaction of $250,000.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Barry J. Simon sold 151,967 shares of the business’s stock in a transaction that occurred on Tuesday, January 20th. The stock was sold at an average price of $7.20, for a total value of $1,094,162.40. Following the completion of the transaction, the director directly owned 3,091,604 shares in the company, valued at $22,259,548.80. The trade was a 4.69% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 226,967 shares of company stock worth $1,531,912 in the last quarter. 69.48% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in IBRX. Slow Capital Inc. purchased a new stake in shares of ImmunityBio in the third quarter worth about $25,000. Truist Financial Corp purchased a new stake in ImmunityBio in the third quarter worth $27,000. Swiss Life Asset Management Ltd bought a new stake in shares of ImmunityBio in the 3rd quarter worth approximately $27,000. WealthPlan Investment Management LLC purchased a new stake in shares of ImmunityBio in the 4th quarter worth approximately $27,000. Finally, Diversify Advisory Services LLC bought a new position in shares of ImmunityBio during the second quarter valued at $27,000. 8.58% of the stock is owned by institutional investors.

ImmunityBio Company Profile

ImmunityBio, Inc is a clinical-stage biotechnology company specializing in the development of novel immunotherapies for cancer and infectious diseases. The company’s research platform centers on harnessing the power of the human immune system—through engineered T cells, natural killer (NK) cells, cytokine superagonists and viral-vectored vaccines—to target and eliminate diseased cells across a range of indications.

Among its lead assets is Anktiva (formerly known as N-803), an interleukin-15 superagonist designed to stimulate NK and T cell activity.